By: Antonio Chirumbolo SUNY 2013
February 15th 2013- The FDA has approved Zioptan (Tafluprost), a preservative free prostaglandin analog, for the treatment of certain kinds of glaucoma. The ophthalmic solution reduces IOP in patients with open angle glaucoma and ocular hypertension. Results from five controlled clinical studies helped spur the approval of the drug, showing that when the drug was administered once in the evening, a mean decrease in pressure from 5mmHg to 8mmHg after six months of trials from baseline levels as high as 23-26mmHg was found. Merck, a major drug company will have the new treatment ready for consumers in March.
